Special Issue

Alternative Cell Death Modes in Regulating Cancer Stem Cells and Therapeutic Strategies

Message from the Guest Editors

In this Special Issue of Cancers, titled "Alternative Cell Death Modes in Regulating Cancer Stem Cells and Therapeutic Strategies", we aim to explore the multifaceted roles of unconventional cell death pathways in shaping CSC biology. Traditional apoptosis has been extensively studied, but emerging evidence suggests the involvement of non-apoptotic cell death modes like necroptosis, ferroptosis, and autophagy in modulating the fate of CSCs. Understanding how these alternative cell death mechanisms intersect with CSC regulation holds great promise for advancing our comprehension of tumorigenesis. We invite original research articles and reviews delving into the intricate connections between alternative cell death modes and CSC dynamics. Join us in exploring cutting-edge research, aiming to unravel the complex relationships between alternative cell death modes and cancer stem cells, ultimately paving the way for novel therapeutic strategies.

Guest Editors

Dr. Mun-Ock Kim

Natural Product Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea

Prof. Dr. Shazib Pervaiz

- 1. National University Cancer Science Institute, National University Health System (NUHS), Singapore, Singapore
- 2. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore

Deadline for manuscript submissions

closed (10 August 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/196082

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

